Latest News and Press Releases

VIENNA, Dec. 16, 2024 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, will be participating in JP Morgan week activities in...

Funding secures ongoing pipeline progress and achievement of preclinical and clinical milestones Oral small molecule INV501: collaboration with Dana-Farber Cancer Institute (DFCI) making good...

Disclosure of the discovery and structure of NX-1607, the first inhibitor of CBL-B to advance into clinical studies.

Multi-center trial of novel autologous cell therapy APN401 leveraging two GMP-compliant manufacturing sites has received regulatory approval and patient recruitment has started;invIOs awarded up to...

APN401 induced prolonged stable disease in two heavily pre-treated patients, using invIOs’s proprietary rapid cell-processing platform technology to manufacture Cbl-b silenced PBMCs and deliver...

VIENNA, Austria, Dec. 14, 2022 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces that CEO Peter...

Poster presentation shows treatment with APN401, an autologous cell therapy product targeting the master immune checkpoint Cbl-b, resulted in stabilization of disease for more than six months in a...

VIENNA, Austria, Oct. 18, 2022 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces that two abstracts on its...

VIENNA, Austria, Dec. 16, 2021 (GLOBE NEWSWIRE) -- invIOs (innovative Immuno-Oncology) GmbH, a privately held biotechnology company developing novel therapies for cancer, is pleased to announce it...